Core Viewpoint - MustGrow Biologics Corp. has successfully closed a non-brokered private placement, raising gross proceeds of $2,000,000 through the sale of 4,000,000 units at a price of $0.50 per unit [1][3] Group 1: Offering Details - Each unit consists of one common share and one common share purchase warrant, with the warrant exercisable for 60 months at an exercise price of $0.70 per share [2] - The offering was conducted under the listed issuer financing exemption, allowing it to bypass the prospectus requirement [4] - The securities sold to Canadian residents will not be subject to a hold period under applicable Canadian securities laws [5] Group 2: Use of Proceeds - The net proceeds from the offering will be allocated for inventory production of the mustard-derived organic biofertility product TerraSanteTM, inventory for agricultural products via NexusBioAg, and general corporate purposes [3] Group 3: Finder's Fees - Eligible finders received a cash fee of $105,000, which is 6.0% of the gross proceeds, along with 210,000 non-transferable common share purchase warrants [6] - Each Finder's Warrant allows the holder to purchase one share at a price of $0.70 for a period of 60 months, subject to a statutory hold period [6] Group 4: Company Overview - MustGrow Biologics Corp. is focused on providing innovative biological and regenerative agriculture solutions, offering eco-friendly alternatives to synthetic chemicals and fertilizers [8] - The company has a portfolio of approximately 110 patents and aims to drive shareholder value through the commercialization of its intellectual property [8] - MustGrow collaborates with agriculture companies, including Bayer AG, to expand its market presence outside North America [8]

Core Viewpoint - MustGrow Biologics Corp. is initiating a non-brokered private placement to raise up to $2,000,000 through the sale of 4,000,000 units at a price of $0.50 per unit, aimed at supporting its agricultural product initiatives and working capital needs [1][3]. Group 1: Offering Details - Each unit consists of one common share and one common share purchase warrant, with the warrant exercisable for 60 months at an exercise price of $0.70 per share [2]. - The closing of the LIFE Offering is expected around January 22, 2026, subject to necessary approvals, including from the TSX Venture Exchange [6]. Group 2: Use of Proceeds - The net proceeds from the LIFE Offering will be allocated for inventory production of the mustard-derived organic biofertility product TerraSanteTM, inventory for agricultural products via NexusBioAg, and general corporate purposes [3]. Group 3: Regulatory Compliance - The offering will be conducted under the listed issuer financing exemption, allowing it to be offered in Canada and certain other jurisdictions without a prospectus [7]. - Units sold to insiders will be subject to a four-month hold period, and the transaction will be considered a related party transaction under Multilateral Instrument 61-101 [9]. Group 4: Company Overview - MustGrow Biologics Corp. specializes in biological and regenerative agriculture solutions, focusing on eco-friendly alternatives to synthetic chemicals and fertilizers [12]. - The company holds approximately 110 patents and aims to drive shareholder value through the commercialization of its proprietary products and technologies [12].

Core Viewpoint - MustGrow Biologics Corp. has successfully closed a non-brokered private placement, raising approximately $2.1 million through the sale of units, along with a repricing of warrants and a shares for debt settlement agreement [1][3][11] Group 1: LIFE Offering - The LIFE Offering consisted of 3,059,731 units sold at a price of $0.70 per unit, generating gross proceeds of approximately $2,141,812 [1] - Each unit includes one common share and one common share purchase warrant, with warrants exercisable for 60 months at an exercise price of $0.90 per share [2] - The net proceeds will be used for inventory production of the mustard-derived organic biofertility product TerraSanteTM, inventory for agricultural products, and general corporate purposes [3] Group 2: Warrant Repricing - The company has repriced 1,721,610 outstanding warrants from a previous private placement, reducing the exercise price from $1.90 to $0.90 per share [7][8] - The repriced warrants include an acceleration provision that allows for an earlier expiry if the share price exceeds $1.08 for ten consecutive trading days [9] - This repricing is pending final approval from the TSX Venture Exchange [10] Group 3: Shares for Debt Settlement - MustGrow is settling approximately $2,385,000 in outstanding principal under unsecured convertible debentures by issuing up to 3,407,134 shares at a deemed price of $0.70 per share [11] - The settlement also includes a cash payment for all accrued and unpaid interest [11] - The shares issued in this settlement will be subject to a statutory hold period of four months and one day [12] Group 4: Insider Participation and Compliance - Certain insiders participated in the LIFE Offering, purchasing a total of 285,716 units, which will be subject to a four-month hold period [13] - The participation of insiders in the LIFE Offering and other transactions is considered a related party transaction under Multilateral Instrument 61-101 [14] - The company is relying on exemptions from formal valuation and minority shareholder approval requirements due to the transaction's market capitalization not exceeding 25% [14] Group 5: Company Overview - MustGrow Biologics Corp. provides innovative biological and regenerative agriculture solutions, focusing on eco-friendly alternatives to synthetic chemicals and fertilizers [15] - The company has a portfolio of approximately 109 patents and collaborates with agriculture companies like Bayer AG for commercialization [15] - MustGrow is publicly traded on the TSX Venture Exchange with approximately 58.9 million common shares outstanding [16]

Core Points - MustGrow Biologics Corp. announced a non-brokered private placement offering of up to $3 million through the sale of 4,285,715 units at a price of $0.70 per unit [1] - The offering includes a proposed repricing of existing warrants and a shares-for-debt settlement offer to debentureholders [1][10] - The net proceeds from the offering will be used for inventory production of its organic biofertility product TerraSanteTM, agricultural product inventory, and general corporate purposes [3] LIFE Offering - Each unit in the LIFE Offering consists of one common share and one common share purchase warrant, with the warrant exercisable at $0.90 for 60 months [2] - The offering is expected to close around August 21, 2025, subject to necessary approvals [6] Warrant Repricing - The company plans to reprice 1,721,610 outstanding warrants from an exercise price of $1.90 to $0.90, with an expiry date of January 16, 2030 [10] - An acceleration provision will be included, allowing for a 30-day exercise period if the share price exceeds $1.08 for ten consecutive trading days [11] Shares for Debenture Debt Settlement - MustGrow intends to offer shares to settle up to $2,585,000 in outstanding principal on unsecured convertible debentures, issuing approximately 3,692,860 shares at a deemed price of $0.70 each [13] - The settlement shares will also be subject to a statutory hold period of four months and one day from issuance [14] Company Overview - MustGrow Biologics Corp. provides innovative biological and regenerative agriculture solutions, focusing on eco-friendly alternatives to synthetic chemicals and fertilizers [18] - The company has a portfolio of approximately 112 patents and collaborates with agriculture companies like Bayer AG for commercialization [18]